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Abstract
Background: A genome-wide association scan with subsequent replication study that involved over 67,000
individuals of European ancestry has produced evidence of association of single nucleotide polymorphism
rs2277831 to primary osteoarthritis (OA) with a P-value of 2.9 × 10
-5. rs2277831, an A/G transition, is located in an
intron of MICAL3. This gene is located on chromosome 22q11.21 and the association signal encompasses two
additional genes, BCL2L13 and BID. It is becoming increasingly apparent that many common complex traits are
mediated by cis-acting regulatory polymorphisms that influence, in a tissue-specific manner, gene expression or
transcript stability.
Methods: We used total and allelic expression analysis to assess whether the OA association to rs2277831 is
mediated by an influence on MICAL3, BCL2L13 or BID expression. Using RNA extracted from joint tissues of 60
patients who had undergone elective joint replacement surgery, we assessed whether rs2277831 correlated with
allelic expression of either of the three genes by: 1) measuring the expression of each gene by quantitative PCR
and then stratifying the data by genotype at rs2277831 and 2) accurately discriminating and quantifying the mRNA
synthesised from the alleles of OA patients using allelic-quantitative PCR.
Results: We found no evidence for a correlation between gene expression and genotype at rs2277831, with P-
values of 0.09 for BCL2L13, 0.07 for BID and 0.33 for MICAL3. In the allelic expression analysis we observed several
examples of significant (p < 0.05) allelic imbalances, with an allelic expression ratio of 2.82 observed in BCL2L13
(P = 0.004), 2.09 at BID (P = 0.001) and the most extreme case being at MICAL3, with an allelic expression ratio of
5.47 (P = 0.001). However, there was no correlation observed between the pattern of allelic expression and the
genotype at rs2277831.
Conclusions: In the tissues that we have studied, our data do not support our hypothesis that the association
between rs2277831 and OA is due to the effect this SNP has on MICAL3, BCL2L13 or BID gene expression. Instead,
our data point towards other functional effects accounting for the OA associated signal.
Background
Osteoarthritis (OA) is a common disease of the synovial
joint characterized by cartilage loss and is often accompa-
nied by alteration in the normal function of other tissues
of the articulating joint [1]. Based on epidemiological stu-
dies, the disease is known to have a major genetic compo-
nent, although elucidating this has proven challenging [2].
This is a reflection of the heterogeneity associated with
the disease, with severe OA being a clinical end-point
reached from a multitude of starting points. Genome-wide
association scans (GWASs) are now being employed as
powerful, objective tools for mapping susceptibility loci of
complex diseases including OA [3,4]. The resulting signals
originate from regions of the genome that do not harbour
obvious OA candidates and an example of this came from
stage one of the recently published arcOGEN GWAS [5].
In an analysis of over 67,000 individuals of European des-
cent this study identified, amongst other signals, an asso-
ciation to SNP rs2277831 (A/G), with a P-value of 2.9 ×
10
-5 and an odds ratio for allele G of 1.07 in knee and/or
hip OA.
rs2277831 is located within intron 32 of the MICAL3
gene, which codes for the microtubule-associated monoxy-
genase, calponin and LIM domain containing 3 protein.
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cle transport system in mammalian cells through the
interaction with Rabs, which are small GTPases [6,7]. Two
additional genes map close by and are encompassed by
the association signal. These are BCL2L13 (also known as
BCL-Rambo), which codes for the BCL2-like 13 (apoptosis
facilitator) protein, and BID, which codes for the BH3
interacting domain death agonist protein. The BCL2L13
protein has structural homology to BCL2, and is thought
to induce apoptosis through the activation of caspase-3
[8]. The BID protein is also proapoptotic and is cleaved by
Caspase-8. The cleaved form translocates to the mitochon-
dria where it forms heterodimers with BAX or BCL2 and
triggers the release of cytochrome c, leading to the activa-
tion of apoptotic pathways [9]. Scrutinizing public data-
bases reveals that MICAL3 gene is expressed in various
tissue types, including adipose tissue, blood, bone, brain,
cartilage, heart, liver, kidney and muscle. BCL2L13 and
BID expression are also observed in many tissue types.
As the number of susceptibility loci that are identified for
common human diseases increases, it is becoming clear
that many, if not the majority, of associated alleles contri-
bute to disease risk by acting as expression quantitative
trait loci (eQTLs), influencing the expression or stability of
a transcript [10,11]. In the majority of cases eQTLs act in
an organ or even tissue specific manner. It is important
therefore to study RNA extracted from tissues relevant to
the disease when assessing the potential effect of eQTLs.
We hypothesized that the OA association to rs2277831
may be marking an eQTL. To assess this we have mea-
sured the overall expression of BCL2L13, BID and
MICAL3 using real time reverse transcription PCR and
stratified the expression by the genotype at rs2277831. We
also tested for allelic expression imbalance of BCL2L13,
BID and MICAL3 using transcript SNPs and assays that
can accurately discriminate and quantify the mRNA
synthesised from each allele. We examined RNA extracted
from the joint tissues of patients undergoing elective joint
replacement surgery.
Methods
Patients
Joint tissues from 60 individuals who had undergone elec-
tive joint replacement of the hip (total hip replacement,
T H R )o rt h ek n e e( t o t a lk n e er e p l a c e m e n t ,T K R )w e r e
obtained and nucleic acids were extracted as described
previously [12]. The tissues collected were cartilage, fat
pad, synovium, cancellous bone and osteophyte. Of these
60 individuals, 59 patients had OA and one patient did
not have clinical OA but had undergone a neck-of-femur
(NOF) fracture. The Newcastle and North Tyneside
research ethics committees granted ethical approval for
the collection (REC reference number 09/H0906/72) and
informed consent was obtained from each donor.
cDNA synthesis
2.2 μgo fR N Aw a sD N a s et r e a t e dw i t hT u r b oD N a s e( 2
units; Ambion) according to the manufacturer’s protocol.
Reverse transcription was carried out using the Super-
Script First-Strand cDNA Synthesis kit (Invitrogen)
according to the manufacturer’s instructions. The synthe-
sised cDNA was PCR amplified using primers located in
different exons, that is, the amplimer spans one or more
introns if the target template were DNA. The use of such
primers distinguishes cDNA products from any products
that may result from residual genomic DNA contamina-
tion. The PCR products were electrophoresed through a
3% weight/volume agarose gel containing ethidium bro-
mide. Only cDNA samples that produced appropriate
sized product were taken forward for allelic expression
imbalance analysis.
Qualitative gene expression
The expression of BCL2L13, BID and MICAL3 in cDNA
synthesised from joint tissue RNAs was assessed using the
following primers: BCL2L13,5 ’GGAATTGACAA-
GACGTGGTC3’ and 5’GCTTTCTGTGTGCCAACTC
TGG3’; BID,5 ’AGACATCATCCGGAATATTGC3’ and
5’TGTGAAAGACATCACGGAGC3’; MICAL3,5 ’GTG
GACTCTGGAAAGCACAG3’ and 5’CAGCTTGGCAT
TCAGTTCCTC3’.
Quantitative gene expression analysis
RNA from cartilage tissue from 32 patients was extracted
and cDNA was synthesised as described above. Quantita-
tive gene expression of BCL2L13, BID and MICAL3 was
then measured by real time reverse transcription PCR
using custom designed TaqMan primers and probes
(Integrated DNA Technologies; Additional file 1). The
reactions were performed in triplicate on an ABI PRISM
7900HT Sequence Detection System. The expression was
measured relative to the housekeeping genes 18S,
GAPDH and HPRT1. The delta Ct value was calculated
using the formula: Delta Ct = Ct (test gene) - Ct (average
of control genes).
Cartilage DNA from the 32 patients was used to geno-
type the patients for the associated SNP rs2277831, as
described below. For each gene, the delta Ct values for
each patient were plotted against the rs2277831 genotype
and linear regression was used to determine if gene
expression relative to genotype differed significantly from
the null.
SNP genotyping
For the allelic expression analysis, we studied eight tran-
script SNPs, three in BCL2L13,o n ei nBID and four in
MICAL3 (Figure 1). The linkage disequilibrium (LD)
between rs2277831 and the transcript SNPs apart from
rs5992854 was low (Table 1 and Additional file 2).
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Page 2 of 11Genotyping of these SNPs, and of the OA associated SNP
rs2277831, was carried out by restriction fragment length
polymorphism (RFLP) analysis. Initially 50 ng of genomic
DNA from patient tissue was PCR amplified in a 15 μl reac-
tion using SNP specific forward and reverse primers (Addi-
tional file 3). The PCR products were then incubated with 5
μl of a digestion mix containing the corresponding restric-
tion enzyme (5 U; New England Biolabs; Additional file 3),
1.5 μl of the recommended NEB buffer (10 x), BSA (100 x)
where required and water. Digestion reactions were incu-
bated for 3 hours at the optimum temperature for the
restriction enzyme. The digested products were then elec-
trophoresed through agarose as described above.
Allelic expression analysis
Allelic expression imbalance was assessed using Sequenom
assays for six of the eight transcript SNPs (rs4488761,
rs2587100, rs11917, rs9967, rs1057721, rs4819639) and
assessed using quantitative real time PCR genotyping
assays for the remaining two SNPs (rs5992854 and
rs11538). Patients who were heterozygous for one or more
of the eight SNPs were selected for allelic expression
imbalance analysis.
Sequenom analysis involves a single-base primer exten-
sion into the SNP of interest using dideoxyNTPs
(ddNTPs). The two alleles at the SNP are then distin-
guished using the difference in mass between the
ddNTPs that are incorporated into the extension primer.
Sequenom assays (Additional file 4) were designed using
the online ‘MySequenom Genotyping Tools’ https://
www.mysequenom.com/Tools. The extension primer
used for one SNP typically differs in mass from the
extension primers used for other SNPs, thus enabling
multiplexing. We prepared two multiplex reactions for
MICAL3 BCL2L13 BID
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Figure 1 Relative positions of the selected transcribed SNPs. The OA associated variant rs2277831 is boxed. Arrows indicate the direction in
which each gene is transcribed.
Table 1 The eight transcript SNPs studied in this report
SNP Position on chr. 22 on NCBI genome build 37.3 Alleles MAF* Gene Location of SNP in gene Pairwise linkage
disequilibrium relative to
the OA associated SNP
rs2277831
D’ r
2
rs4488761 18209613 A/G 0.46 BCL2L13 3’UTR/exonic
^ 0.11 0.00
rs2587100 18210704 C/G 0.40 BCL2L13 3’UTR 0.02 0.00
rs9967 18211205 C/T 0.38 BCL2L13 3’UTR 0.21 0.01
rs11538 18220831 T/C 0.18 BID 3’UTR/exonic
^ 0.12 0.00
rs5992854 18300240 T/C 0.32 MICAL3 exonic 1.00 0.71
rs11917 18343011 G/T 0.41 MICAL3 3’UTR 0.76 0.11
rs1057721 18343843 G/A 0.41 MICAL3 3’UTR 0.78 0.13
rs4819639 18347127 C/T 0.29 MICAL3 3’UTR 0.74 0.06
*Minor allele frequency in Europeans (dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/
^Multiple predicted splice isoforms result in different potential locations
in the transcript
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Page 3 of 11the six SNPs. DNA and the respective cDNA were ampli-
fied separately using the forward and reverse primers
listed in Additional file 4 in a 15 μl multiplex reaction.
The reactions were performed in four replicates. A 5 μl
aliquot of each PCR product was then incubated with 0.5
U of Shrimp alkaline phosphatase (SAP; Sequenom) at
37°C for 40 minutes and 85°C for 5 minutes. The multi-
plex extension reaction was then carried out in a 9 μl
volume with 10 × iPLEX buffer, iPLEX termination mix,
extension primer mix (primers at 7 to 14 μM each in a
multiplex pool) and iPLEX enzyme (Sequenom). The
extension reaction products were then purified with
SpectroCLEAN (Sequenom), arrayed on to spots on a
SpectroCHIP and analysed in a Sequenom MassARRAY
Analyzer. The SpectroTYPER software (Sequenom) gen-
erates a peak for each extension fragment at the expected
mass, which corresponds to the amount of each allele in
the sample analysed.
Quantitative real time PCR genotyping assays are stan-
dard real time assays except that they employ a probe
(FAM or VIC labelled) specific to each of the two alleles at
a SNP. Readymade TaqMan genotyping assays for
rs5992854 and rs11538 were purchased from Applied Bio-
systems. Real time PCR was carried out according to the
manufacturer’s instructions on an ABI PRISM 7900HT
Sequence Detection System. The allelic ratios were calcu-
lated using the formula (2^-FAM Ct)/(2^-VIC Ct).
For each Sequenom and real time PCR assay, four
replicates were performed per DNA and per cDNA. For
each assay, the ratios between the amounts of each allele
in every sample were calculated for genomic DNA and
cDNA. For each sample the average allelic ratio for
genomic DNA, which represents the 1:1 ratio, was then
used to normalise the average cDNA ratio to generate a
normalised allelic ratio using the following formula:
Normalised allelic ratio =
Average allelic ratio of cDNA
Average allelic ratio of gDNA
Tissue samples were considered to show an allelic
imbalance if the fold difference in expression from the two
alleles was 20% or greater. A two-tailed Mann-Whitney
exact test was performed to compare the distribution
between the allelic ratios of the DNA replicates and the
cDNA replicates. A Kruskal-Wallis test was performed to
assess the association between allelic expression and the
genotype at rs2277831.
Results
Expression of BCL2L13, BID and MICAL3 was observed
in the five joint tissues analysed; cartilage, fat pad, syno-
vium, cancellous bone and osteophyte (data not shown).
We quantitatively measured the expression of
BCL2L13, BID and MICAL3 in cartilage RNA in 32 OA
patients and stratified the expression data by genotype
at the OA associated SNP rs2277831. Two patients were
homozygous GG, 9 were heterozygous and 21 were
homozygous AA. There was no significant correlation
between genotype at rs2277831 and the expression of
BCL2L13, BID or MICAL3, with P-values of 0.09, 0.07
and 0.33, respectively (Figure 2, Additional file 5).
Correlating genotype with overall gene expression is
vulnerable to the natural fluctuation in gene expression,
and as such is liable to generating false-negative results.
Directly testing for allelic expression differences can
overcome this. We therefore subsequently identified 33
patients who were heterozygous at one or more of the
eight transcript SNPs (Table 2). Thirty-two of the 33
were OA patients whereas patient 42 had undergone
joint surgery due to a hip fracture. For two of the OA
patients we had collected more than one tissue type: fat
pad and synovium for patient 52, cancellous bone and
osteophyte for patient 60. For all other patients we had
collected only one tissue type per patient.
Twenty-eight of the 33 patients were heterozygous for
o n eo rm o r eo ft h et h r e eBCL2L13 transcript SNPs.
Twelve of the 28 demonstrated allelic expression imbal-
ance (AEI) when applying the arbitrary threshold of a
20% or greater difference in expression between alleles
(data in bold in Table 2). Of these 12 patients, three were
heterozygous for the associated SNP rs2277831 (patients
35, 54 and 55), three were homozygous GG at rs2277831
and six were homozygous AA at rs2277831. AEI at
BCL2L13 did not therefore correlate with genotype at
rs2277831. The largest allelic ratio observed at BCL2L13
was 2.82 (P = 0.004) at transcript SNP rs2587100
for patient 13 (Figure 3), who is homozygous AA at
rs2277831.
Eleven patients were heterozygous for the BID tran-
script SNP rs11538. Three of the eleven demonstrated
AEI at the 20% threshold, patients 37, 57 and 58 (data in
bold in Table 2). There was no correlation between geno-
type at rs2277831 and AEI at BID, with all three patients
being homozygous AA at this SNP. The largest allelic
ratio observed at BID was 2.09 (P = 0.001) in patient 57
(Figure 3).
Twenty-seven patients were heterozygous for one or
more of the four MICAL3 transcript SNPs. Nineteen of
the 27 patients demonstrated AEI at the 20% threshold
(data in bold in Table 2). Of these 19, five were hetero-
zygous for the associated SNP rs2277831 (patients 4, 35,
45, 55 and 59), one was homozygous GG at rs2277831
and 13 were homozygous AA. AEI at MICAL3 did not
therefore correlate with genotype at rs2277831. The lar-
gest allelic ratio observed at MICAL3, and at any of the
three genes studied, was 5.47 (P = 0.001) at transcript
SNP rs5992854 for patient 38 (Figure 3), who is homo-
zygous AA at rs2277831.
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Page 4 of 11Figure 2 Expression in the cartilage of 32 OA patients of BCL2L13, BID and MICAL3 stratified by genotype at the OA associated SNP
rs2277831. The data points represent the average of the three replicates for each sample. The expression of (A) BCL2L13, (B) BID and (C) MICAL3
was compared to the average of the housekeeping genes and the delta Ct values were plotted against the genotype at the associated SNP
rs2277831. The horizontal bars represent the mean plus the standard deviation. The genotype at rs2277831 did not correlate with gene
expression with P-values of 0.09 for BCL2L13, 0.07 for BID and 0.33 for MICAL3.
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Page 5 of 11Table 2 Allelic expression analysis for 33 patients
BCL2L13 BID MICAL3
Patient
no.
Sex Age at surger y
(years)
Tissue* rs4488761 rs2587100 rs9967 rs11538 rs2277831 rs5992854 rs11917 rs1057721 rs4819639
Gen
^ AER†
(A/G)
Gen
^ AER†
(C/G)
Gen
^ AER†
(C/T)
Gen
^ AER†
(T/C)
Gen
^ Gen
^ AER†
(T/C)
Gen
^ AER†
(T/G)
Gen
^ AER†
(G/A)
Gen
^ AER†
(C/T)
1 F 55 Cart (K) AG 1.04 CG 0.67 CT 0.71 TC 0.90 GG CC - GG - AA - CC -
33 M 74 Cart (K) AG 1.15 CG 1.03 CT 0.91 TT - GG CC - GG - AA - CC -
3 M 82 Cart (K) AA - CG 0.83 TT - TC 1.10 GA TC 1.13 GG - AA - CT 0.96
4 M 57 Cart (K) AG 0.95 CG 0.87 CT 1.09 TC 1.06 GA TC 0.56 TG 1.30 GA 2.10 CT 1.38
34 F 57 Cart (K) AA - GG - TT - TT - GA TC 1.14 TG 0.88 GA 0.84 CT 0.90
35 M 58 Cart (K) AA - CG 0.78 TT - TT - GA TC 1.30 TG 1.11 GA 0.87 CT 1.02
36 M 71 Cart (K) GG - GG - CC - TT - GA TC 1.02 GG - AA - CC -
37 F 72 Cart (K) AG 1.09 CG 0.91 CT 1.15 TC 1.54 AA TT - TG 1.51 GA 0.85 CT 0.87
38 M 64 Cart (K) AG 0.91 CG 1.01 CT 1.09 TT - AA TC 5.47 TT - GG - CC -
39 M 76 Cart (K) GG - CG 0.88 CT 1.33 TT - AA TT - TG 1.01 GA 1.51 CT 0.82
13 F 66 Cart (K) AG 1.40 CG 2.82 CT 0.57 TT - AA TC 1.22 TT - GG - TT -
26 F 67 Cart (H) AG 1.67 CG 1.98 CT 1.01 TT - AA TC 0.83 TT - GG - TT -
40 F 76 Cart (H) AG 1.04 CG 0.99 CT 1.22 TC 1.01 AA TT - TG 0.76 GA 1.14 CT 1.49
41 F 50 Cart (H) GG - CG 0.94 CC - TT - AA TT - TT - GG - CT 0.83
42 M 83 Cart (H) AG 0.97 CG 1.00 CT 1.18 TC 0.96 AA TC 1.03 TG 1.00 GA 1.16 CT 0.93
43 M 62 Fat pad AG 1.06 CG 1.00 CT 1.01 TC 0.94 GG CC - TG 1.09 GA 1.39 CC -
44 M 57 Fat pad AG 1.01 GG - CT 0.80 TT - GG TT - GG - AA - CC -
45 M 76 Fat pad GG - GG - CC - TT - GA TC 1.92 GG - AA - CC -
46 M 79 Fat pad GG - GG - CC - TT - GA TC 0.96 TG 1.03 GA 1.13 CT 1.02
47 M 58 Fat pad AG 0.99 CC - TT - TT - GA TT - GG - AA - CC -
48 M 58 Fat pad AG 1.02 CG 1.00 CT 1.36 TT - AA TT - TG 0.80 GA 0.63 CT 1.09
49 F 42 Fat pad AG 1.05 CG 0.94 CT 1.15 TT - AA TT - TG 2.13 GA 1.22 CT 0.92
50 M 71 Fat pad GG - CG 1.00 CT 1.13 TT - AA TT - TG 1.27 GA 1.23 CC -
51 F 67 Fat pad AG 0.95 CG 1.05 CT 0.95 TT - AA TC 0.75 TT - GG - TT -
52 F 78 Fat pad AG 1.15 CG 0.89 CT 0.92 TT - AA TT - GG - AA - CC -
53 M 74 Syn AG 0.80 GG - CT 1.33 TT - GG CC - GG - AA - CC -
54 M 62 Syn AG 0.99 CG 0.85 CT 1.23 TT - GA TC 1.12 GG - AA - CC -
55 M 67 Syn AG 0.97 CG 0.98 CT 1.32 TC 0.83 GA TC 0.81 TG 0.57 GA 0.75 CT 1.24
56 M 60 Syn AG 1.11 GG - CT 1.14 TT - AA TT - TG 1.19 GA 1.32 CC -
57 M 69 Syn AG 0.85 CG 1.98 CT 0.72 TC 2.09 AA TT - TT - GG - CT 0.77
58 F 54 Syn AG 0.90 CG 1.16 CT 1.19 TC 1.56 AA TT - TG 1.85 GA 1.89 CC -
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1Table 2 Allelic expression analysis for 33 patients (Continued)
52 F 78 Syn AG 1.00 CG 0.95 CT 1.02 TT - AA TT - GG - AA - CC -
59 F 72 Can bn AA - CG 1.10 TT - TC 1.14 GA TC 0.96 TG 0.86 GA 1.23 CT 1.07
60 M 86 Can bn GG - GG - CC - TT - AA TT - TG 1.43 GA 1.10 CC -
60 M 86 OP GG - GG - CC - TT - AA TT - TG 1.27 GA 1.31 CC -
*Cart (H), hip cartilage; Cart (K), knee cartilage; Syn, synovium; Can bn, cancellous bone;
OP, osteophyte
^Gen, genotype
†AER, allelic expression ratio
Bold text denotes allelic expression imbalance (AEI) at the 20% threshold.
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Figure 3 Allelic expression imbalance in patients who showed the largest allelic ratios at BCL2L13, BID and MICAL3.D a t ap o i n t s
represent log2 of the normalised allelic ratio of genomic or cDNA for each replicate. A value of 0 on the Y-axis denotes an allelic ratio of 1:1. (A)
Patient 13 demonstrated a 2.82 fold greater expression of the C allele relative to the G allele (P = 0.004) at BCL2L13 SNP rs2587100, (B) patient 57
demonstrated a 2.09 fold greater expression of the T allele relative to the C allele (P = 0.001) at BID SNP rs11538, (C) patient 38 demonstrated a
5.47 fold greater expression of the T allele relative to the C allele (P = 0.001) at MICAL3 SNP rs5992854.
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Page 8 of 11We noted that in some individuals who were hetero-
zygous for more than one transcript SNP from a parti-
cular gene, the AEI pattern observed was not always
consistent between the transcript SNPs. For example,
for BCL2L13 patient 1 shows AEI at rs2587100 (0.67)
and at rs9967 (0.71), but not at rs4488761 (1.04).
BCL2L13 has 14 transcript isoforms and rs4488761
exists in nine of these whereas, rs2587100 and rs9967
A 
C 
B 
D 
E  F 
G  H 
Figure 4 Allelic expression imbalance in patients at the eight transcript SNPs studied.
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Page 9 of 11exist in five. Such variability could account for such AEI
differences. We therefore plotted the average allelic
expression ratios for the heterozygotes at the eight tran-
script SNPs and stratified the data by genotype at
rs2277831 (Figure 4). At any of the transcribed SNPs,
the Kruskal-Wallis test showed no significant evidence
of a difference in the allelic expression ratios between
the different genotypes at rs2277831 (P-values of 0.45 at
rs4488761, 0.11 at rs2587100, 0.20 at rs9967, 0.15 at
rs11538, 0.88 at rs5992854, 0.35 at rs11917, 0.41 at
rs1057721 and 0.53 at rs4819639).
The averaged log2 of the normalised allelic ratios are
shown for each patient, categorised according to the
genotype at the associated SNP, rs2277831. The shaded
area represents a 20% fold difference in expression
between the two alleles
Overall, we have studied hip cartilage, knee cartilage,
fat pad, synovium, cancellous bone and osteophyte and
although we observed AEI for one or more of the tis-
sues in each gene, the AEI does not correlate with geno-
type at the OA associated SNP rs2277831.
Discussion
It has become increasingly apparent that most common
traits are influenced by large numbers of alleles that
individually have small effects [13]. It is also becoming
clear that many if not the majority of complex trait
alleles influence the expression of the gene by modulat-
ing transcription or transcript stability [11]. In OA, the
GDF5 SNP rs143383 is a very good example of this.
GDF5 codes for growth and differentiation factor 5, an
extracellular signalling molecule that participates in the
development and maintenance of the synovial joint.
rs143383 is a T to C transition located in the 5’ untrans-
lated region of GDF5 and it shows compelling associa-
tion to OA in European and Asian cohorts (reviewed in
[2]). Functional studies have suggested that rs143383
may itself be the polymorphism influencing OA suscept-
ibility at this locus, with the OA associated T allele
mediating reduced GDF5 transcription relative to the C
allele in all joint tissues so far tested [14]. We therefore
hypothesised that the recently reported knee and hip
OA association signal at chromosome 22q11.21,
detected at SNP rs2277831, may mediate its effect on
OA susceptibility by modulating the expression of one
or more of the three genes from within the signal. We
chose to focus our expression studies on joint tissues
from patients who had undergone joint replacement
surgery rather than a tissue unrelated to OA, such as
blood.
We first looked at overall expression of BCL2L13, BID
and MICAL3 in cartilage tissue RNA stratified by geno-
type at rs2277831, with no significant correlations
observed.
We subsequently tested each gene for the activity of
cis-regulatory polymorphisms by measuring AEI. Our
results revealed that AEI was common and was not
restricted to a particular tissue type. If our hypothesis
were correct, namely that the OA associated G allele of
rs2277831 was a marker for altered expression of one or
more of the three genes tested then we would predict
that a heterozygote for this SNP would tend to demon-
strate AEI. However, we did not observe any correlation
between genotype at rs2277831 and AEI, such that an
individual heterozygous for rs2277831 was no more
likely to demonstrate AEI at one of the three genes than
an individual homozygous at this SNP.
Conclusions
Overall our study reveals that BCL2L13, BID and
MICAL3 are subject to cis-acting polymorphism/s that
influence the expression of the genes in the joint tissues
of patients who have undergone surgery. Our data do
not however support a role for such cis-regulation at
these genes as accounting for the OA association signal
at chromosome 22q11.21. Other functional effects are
presumably involved.
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